Le Lézard
Classified in: Health, Science and technology
Subjects: SVY, TDS, WOM, TRI

Sojournix Poster Presentation At ENDO 2019 Features Positive Data From SJX-653 Proof-of-Mechanism Clinical Study


WALTHAM, Mass., March 23, 2019 /PRNewswire/ -- Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women's health and neuroendocrine disorders, today presented positive data from a first-in-human Phase 1 clinical study of SJX-653 at ENDO 2019, the Endocrine Society's 101st Annual Meeting held in New Orleans, LA.  In a poster presentation titled "SJX-653, A Novel Selective NK3 Antagonist, Demonstrates Activity on Pharmacodynamic Markers of NK3 Target Engagement," study results were presented in which SJX-653 demonstrated clinical proof-of-mechanism through statistically significant and dose-dependent activity on pharmacodynamic markers of NK3 receptor target engagement, with doses as low as 15 mg achieving near maximal effect, a long plasma half-life supporting once-daily (QD) dosing, and a well-tolerated profile. SJX-653 is a novel, selective, neurokinin-3 (NK3) antagonist in development as a once-daily (QD) non-hormonal therapy for moderate to severe vasomotor symptoms (VMS), or "hot flashes," due to menopause.

(PRNewsfoto/Sojournix)

This randomized, placebo-controlled, double-blind, single ascending dose (SAD) study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered SJX-653.  To demonstrate proof-of-mechanism, the study was performed in healthy adult men (N=42) and measured changes in luteinizing hormone (LH) and total testosterone (T). LH and T levels in men are known to be especially sensitive to NK3 antagonists and therefore, LH and T have become established pharmacodynamic markers of NK3 receptor target engagement in the brain.

"We are pleased to present these data at ENDO demonstrating clinical proof-of-mechanism for SJX-653 through reductions in known pharmacodynamic markers of NK3 receptor target engagement," said Philip Graham, PhD, Senior Vice President, Strategy and Product Development at Sojournix.  "In this study, SJX-653 demonstrated statistically significant pharmacodynamic activity at doses of 15 mg and above as well as an attractive pharmacokinetic profile including a 10-13 hour half-life consistent with once-daily (QD) dosing."

"Our successful proof-of-mechanism study with SJX-653 represents an important development milestone for Sojournix as we advance SJX-653 for the treatment of moderate to severe vasomotor symptoms due to menopause, a condition with a well-recognized and significant unmet medical need for a safe and effective non-hormonal treatment option," said Daniel Grau, President and CEO of Sojournix.

Highlights of the Sojournix Poster Presentation at ENDO include:

About SJX-653

SJX-653 is a novel and selective neurokinin-3 (NK3) antagonist in clinical development as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms (commonly called "hot flashes") due to menopause.

About Neurokinin-3 (NK3)

Vasomotor symptoms are believed to be caused by excessive NK3 signaling in the median preoptic nucleus, an area of the brain responsible for regulating body temperature.  During menopause, the decline in estrogen levels leads to an over-production of neurokinin B (NKB), an endogenous neurotransmitter that binds to and activates NK3 receptors in the median preoptic nucleus.  By reducing the excessive signaling of NKB at the NK3 receptor, NK3 antagonism has the potential to alleviate menopausal vasomotor symptoms.  As a mechanism of action for treating vasomotor symptoms, NK3 antagonism is clinically validated and has demonstrated efficacy comparable to hormone therapy.  In addition, a human genome study has revealed a genetic link between vasomotor symptoms and the tachykinin 3 gene that encodes the NK3 receptor.

About Vasomotor Symptoms (VMS)

Vasomotor symptoms (VMS) are sudden sensations of intense heat, or "hot flashes," sweating and skin reddening which can occur frequently, disrupting both sleep and daily activities, and are associated with increased rates of insomnia, depression and cognitive impairment.  Over 2 million women in the United States enter menopause each year and the majority experience VMS, with symptoms typically persisting for many years during and after menopause. Current treatment options are limited to hormone therapy, which patients and physicians often avoid due to safety concerns, or non-hormonal agents, known to have limited efficacy.  As a result, there is a well-recognized and significant unmet medical need for a safe and effective non-hormonal therapy for menopausal VMS.

VMS is also a common and sometimes debilitating side effect of commonly-used treatments for breast and prostate cancer, making it challenging for patients to adhere to their cancer treatment.  Addressing drug-induced VMS in this setting represents another potential development opportunity for SJX-653.

About Sojournix

Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women's health and neuroendocrine disorders. We are developing SJX-653, a novel and selective neurokinin 3 (NK3) antagonist, as an oral, once-daily, non-hormonal therapy for moderate to severe vasomotor symptoms due to menopause (commonly called "hot flashes"). Vasomotor symptoms (VMS) are sudden sensations of intense heat, sweating, and skin reddening which can occur frequently, disrupting both sleep and daily activities, and are associated with increased rates of insomnia, depression, and anxiety. Highly prevalent among menopausal women, VMS typically persist for many years during and after menopause. Current treatment options are limited to hormone therapy, which is often avoided due to safety concerns, or non-hormonal agents known to have limited efficacy. NK3 antagonism is a clinically and genetically validated new approach that targets the underlying cause of VMS by reducing excessive NK3 signaling in the area of the brain that regulates heat dissipation. To learn more about Sojournix, please visit www.sojournixpharma.com.

SOURCE Sojournix


These press releases may also interest you

at 08:35
Cozmix is pleased to announce the immediate availability of AlignMix 2019, their powerful sales territory mapping software. The new version is a major upgrade and builds on the user-friendly and powerful capabilities of previous versions of AlignMix....

at 08:35
Lo Village's debut single set a new record for the group this week, surpassing more than one million streams on Spotify. Arguably the trio's most popular song (the next three top-streamed singles - Lil Mama, 7:45 and Real One Pt. 2 - have about one...

at 08:35
Messaging Architects, an eMazzanti Technologies Company and New Jersey information governance and email migration services provider, today announced that Carl Mazzanti, President, eMazzanti Technologies was spotlighted in the April, 2019 edition of...

at 08:32
Future FinTech Group Inc. (FTFT)("Future FinTech", "FTFT" or "the Company"), a financial technology company and integrated producer of fruit-related products, today announced that the company's management is scheduled to present at the 2019 Planet...

at 08:30
Baidu, Inc. , the leading Chinese language Internet search provider, today announced that it will report its financial results for the first quarter ended March 31, 2019, after the U.S. market closes on May 16, 2019. Baidu's management will hold an...

at 08:30
Criteo S.A. , the advertising platform for the open Internet, will announce its financial results for the first quarter ended March 31, 2019 on Tuesday, April 30, 2019. On that day, JB Rudelle, CEO, and Benoit Fouilland, CFO, will host a conference...



News published on 23 march 2019 at 14:00 and distributed by: